SCHEMBL687589

SCHEMBL687589

CC(NC(=O)NC(N)=O)(C1CCCCC1)C1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 9/20 0.39
SSTR4 P31391 2/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 1/20 0.35
ATM Q13315 1/20 0.35
ALDH1A1 P00352 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LMNA P02545 1/20 0.33
ALOX12 P18054 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP3A4 P08684 1/20 0.32
EPHX2 P34913 1/20 0.32
CRBN Q96SW2 1/20 0.31
PDK1 Q15118 1/20 0.31
PDK2 Q15119 1/20 0.31
PDK3 Q15120 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL689274 0.77 EPHX1 (0.35) EPHX1SSTR4MEN1KMT2AMAPT
SCHEMBL3983126 0.73 MEN1 (0.37) EPHX1SSTR4MEN1KMT2AALDH1A1
SCHEMBL25039061 0.69 CRBN (0.43) EPHX1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3075390 0.67 EPHX1 (0.67) EPHX1MEN1KMT2AMAPTATM
SCHEMBL3079201 0.67 EPHX1 (0.36) EPHX1MEN1KMT2AMAPTALDH1A1
SCHEMBL3149064 0.66 EPHX1 (0.38) EPHX1SSTR4MEN1KMT2AMAPT
SCHEMBL8283504 0.66 EPHX1 (0.38) EPHX1SSTR4MEN1KMT2AMAPT
SCHEMBL28087437 0.66 EPHX1 (0.47) EPHX1MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL28194093 0.66 HDAC8 (0.50) EPHX1MAPTALDH1A1
SCHEMBL29416278 0.65 EPHX1 (0.37) EPHX1SSTR4MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904438-B1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK AS (DK) 2012-02-29 EP claimed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US claimed
EP-1904438-B1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK AS (DK) 2012-02-29 EP disclosed
US-7999114-B2 Dicycloalkylcarbamoyl ureas as glucokinase activators NOVO NORDISK A/S (DK) 2011-08-16 US disclosed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators GCK, HK1, GCKR EPHX1 4231/4885SSTR4 3300/4885MEN1 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.